Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of EsoCap.

    Client Virtual Booth

    ESOCAP

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    EsoCap
    Switzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    Malzgasse 9, CH-4052 Basel
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://esocapbiotech.ch/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/esocap-biotech/?originalSubdomain=ch
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    EsoCap Reports Positive Topline Results from ACESO Phase II Trial Investigating ESO-101 in Eosinophilic Esophagitis

    Details:

    ESO-101 (mometasone furoate), designed as a locoregional, esophagus-adjusted drug formulation and novel delivery system to optimize mucosal contact time and maximize esophageal deposition, has the potential to provide significant clinical benefits to eosinophilic esophagitis.


    Lead Product(s): Mometasone Furoate

    Therapeutic Area: Gastroenterology Product Name: ESO-101

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 05, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    EsoCap Completes Patient Recruitment in ACESO Phase II Trial in Eosinophilic Esophagitis

    Details:

    ESO-101 was designed as a locoregional, esophagus-adjusted drug formulation and novel delivery system to optimize mucosal contact time and maximize esophageal deposition of mometasone furoate. it has the potential to provide significant clinical benefits to EoE patients.


    Lead Product(s): Mometasone Furoate

    Therapeutic Area: Gastroenterology Product Name: ESO-101

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 05, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Esocap Holds a Multidisciplinary Advisory Board Meeting on Barrett's Esophagus

    Details:

    ESO-101 (Mometasone Furoate), EsoCap’s lead product candidate, consists of a capsule with a rolled, thin mucoadhesive film, loaded with the anti-inflammatory corticosteroid, mometasone furoate.


    Lead Product(s): Mometasone Furoate

    Therapeutic Area: Gastroenterology Product Name: ESO-101

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 14, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    EsoCap and Upadia Sign Exclusive Licensing Agreement Combining Eso Cap Technology with Upadia Antibodies for The Treatment of Barrett’s Esophagus

    Details:

    Under the terms of the agreement, Upadia will provide an exclusive licence for its range of highly specific monoclonal antibodies, so EsoCap can develop therapies against BE using EsoCap’s unique, proprietary targeted application technology for upper gastrointestinal tract.


    Lead Product(s): Monoclonal Antibody

    Therapeutic Area: Gastroenterology Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Upadia Holding

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement January 10, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search